, Volume 87, Issue 9, pp 763-765
Date: 26 Mar 2008

JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

A recent mutation located in the JAK2 gene, JAK2 V617F, has been shown to play a transcendental role in the constitutive activation of its tyrosine kinase activity in an important number of cases of Philadelphia negative myeloproliferative disorders (Ph-MPDs). This mutation is a useful tool for diagnosing this diseases because different studies show that this mutation is highly frequent in patients with polycythemia vera (PV) and is present in around 50% of the patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) [1]. Among the clinical features and phenotypes that characterize Ph-MPD patients, thrombotic and hemorrhagic episodes have been shown to be frequent in these patients. Range values for thrombosis at diagnosis fluctuate between 34% to 39% for PV and 10% to 29% for ET [2]. For hemorrhage, the values are much more variable [3].

The mechanisms accounting for the increased risk of thrombosis and hemorrhage in Ph-MPD patients are not well under

This study was supported, in part, by research grants SAF 2004-07535 (MEC) and 03116/PI/05 (Fundación Séneca). L. N-N. is a fellow from Ministerio de Educación y Ciencia (BES-2005-7496). C. M. is Ramón y Cajal investigator from the University of Murcia.